Perspectives on the development of a molecularly targeted agent.

STI571 (Gleevec, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies is explored.

[1]  J. Melo,et al.  The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.

[2]  E. Russell.  Hereditary anemias of the mouse: a review for geneticists. , 1979, Advances in genetics.

[3]  Susan M. Watanabe,et al.  An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity , 1984, Cell.

[4]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[5]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[6]  B. Druker,et al.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[7]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[8]  C. Brannan,et al.  Requirement for mast cell growth factor for primordial germ cell survival in culture , 1991, Nature.

[9]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[10]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[11]  J. Stephenson,et al.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.

[12]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[13]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[14]  A. Pacholczyk.  Faraday Rotation Effect in Extragalactic Radio Sources , 1963, Nature.

[15]  Philippe Soriano,et al.  Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. , 1994, Genes & development.

[16]  J. Stephenson,et al.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia , 1982, Nature.

[17]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .

[18]  E. Canaani,et al.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia , 1985, Nature.

[19]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[20]  Z. Estrov,et al.  Chronic Myelogenous Leukemia: Biology and Therapy , 1999, Annals of Internal Medicine.

[21]  Philippe Soriano.  The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. , 1997, Development.

[22]  D. Tenen,et al.  Reversibility of acute B-cell leukaemia induced by BCR–ABL1 , 2000, Nature Genetics.

[23]  T. Holyoake,et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.

[24]  B. Druker,et al.  STI571: a paradigm of new agents for cancer therapeutics. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[26]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[27]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[28]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[29]  B. Druker,et al.  Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N. Lydon,et al.  Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. , 1997, Blood cells, molecules & diseases.

[31]  S. Goff,et al.  Mice homozygous for the abl m1 mutation show poor viability and depletion of selected B and T cell populations , 1991, Cell.

[32]  C. Sawyers.  Chronic myeloid leukemia. , 1999, The New England journal of medicine.

[33]  B. Chabner.  The oncologic four-minute mile. , 2001, The oncologist.

[34]  B. Druker,et al.  Roots of Clinical Resistance to STI-571 Cancer Therapy , 2001, Science.

[35]  B. Druker,et al.  Chronic myeloid leukemia: current treatment options. , 2001, Blood.

[36]  M. Carroll,et al.  CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.

[37]  R. Bronson,et al.  Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene , 1991, Cell.

[38]  Martin C. Müller,et al.  Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy , 2001 .

[39]  N. Rosenberg,et al.  Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Rowley,et al.  Chromosome translocations: dangerous liaisons revisited , 2001, Nature Reviews Cancer.

[41]  Todd R. Golub,et al.  Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation , 1994, Cell.

[42]  J. Stephenson,et al.  Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia , 1983, Nature.

[43]  G. Jenster,et al.  Acute leukaemia in bcr/abl transgenic mice , 1990, Nature.

[44]  S. Sacchi,et al.  Chronic myelogenous leukemia in nonlymphoid blastic phase , 1999, Cancer.

[45]  B. Druker,et al.  Bcr-Abl inhibition as a modality of CML therapeutics. , 2001, Biochimica et biophysica acta.